Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
With over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications.
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
With deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
Get a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Recombinant human monoclonal antibody expressed in CHO binding to Influenza A hemagglutinin. CR6261 is a monoclonal antibody that binds to a broad range of the influenza virus. Based upon the conservation of the amino acid sequence on this part of hemagglutinin, CR6261 is predicted to neutralize roughly 50% of all flu viruses.
Target
Influenza A hemagglutinin
Type
IgG1 - lambda
Immunogen
The details of the immunogen for this antibody are not available.
Species Reactivity
influenza virus
Expression Host
CHO
Applications
Suitable for use in ELISA, FC, IP, FuncS, IF, Neut, IHC and most other immunological methods.
CAS
1393659-46-5
Predicted N terminal
EVQLVESG
Molecular Weight
Approximately 150 kDa
Purity
>95.0% as determined by analysis by RP-HPLC.
Size
1mg
Storage
At -20°C for one year.
BACKGROUND
Introduction
Influenza A (H1N1) virus is a subtype of influenza A virus and was the most common cause of human influenza (flu) in 2009. Some strains of H1N1 are endemic in humans and cause a small fraction of all influenza-like illness and a small fraction of all seasonal influenza. H1N1 strains caused a few percent of all human flu infections in 2004–2005Other strains of H1N1 are endemic in pigs (swine influenza) and in birds (avian influenza).
Antigen Description
Influenza A virus is a major public health threat. Novel influenza virus strains caused by genetic drift and viral recombination emerge periodically to which humans have little or no immunity, resulting in devastating pandemics. Influenza A can exist in a variety of animals; however it is in birds that all subtypes can be found. These subtypes are classified based on the combination of the virus coat glycoproteins hemagglutinin (HA) and neuraminidase (NA) subtypes.
Keywords
Influenza A Hemagglutinin; Influenza A; H1N1; Group V ((-)ssRNA); Orthomyxoviridae; S-OIV A Hemagglutinin; Swine flu H1